OncoBEAM RAS CRC Kit is used to detect RAS gene mutations in genomic DNA extracted from plasma. Credit: © Sysmex Corporation.

Sysmex has secured the first manufacturing and marketing approval in Japan for the OncoBEAM RAS CRC Kit, which is used for the blood-based circulating tumour DNA molecular testing of KRAS and NRAS gene mutations in patients with colorectal cancer.

The company noted that the product is the first in vitro diagnostic reagent in the country to be used for RAS gene mutation testing using liquid biopsy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The new OncoBEAM is simpler, minimally invasive, and provides detection results on a par with the use of tumour tissue.

It is capable of reducing the physical and mental burden on patients as well as expanding testing opportunities. It also contributes to the determination of treatment methods at an early stage.

OncoBEAM is used to test samples of tumour-derived DNA suspended in the blood of colorectal cancer patients.

As the approach uses BEAMing technology to provide auxiliary test data for the appropriateness of molecularly targeted drugs Cetuximab and Panitumumab for patients with colorectal cancer, doctors will also be able to determine treatment methods.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

OncoBEAM, which received CE Marking certification in March 2016, was developed by Merck and the company’s subsidiary Sysmex Inostics.

For the approval of the method as an in vitro diagnostic reagent in Japan, eight medical facilities were involved in a multi-facility evaluation, including the National Cancer Center Hospital East.

Sysmex plans to launch the OncoBEAM RAS CRC Assay Service for colorectal cancer using a liquid biopsy to detect RAS gene mutations in the blood, at the Sysmex IMP laboratory in the Kobe Biomedical Innovation Cluster.